Study guide
12.2 NICE-Directed Type 2 Therapy & Microvascular Complications
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
12.2 NICE-Directed Type 2 Therapy & Microvascular Complications
Key Takeaways Explain This Topic AI
SGLT2 inhibitors are added to metformin where there is established atherosclerotic cardiovascular disease, heart failure or chronic kidney disease, and cause euglycaemic ketoacidosis and genital mycotic infection.
Pioglitazone is contraindicated in heart failure, bladder cancer and osteoporotic fracture risk; GLP-1 receptor agonists cause nausea and are associated with pancreatitis.
ACE inhibitors or angiotensin receptor blockers are indicated once the albumin:creatinine ratio exceeds 3 mg/mmol in diabetic kidney disease, irrespective of blood pressure.
Last updated: September 2026
3. Guideline-Directed Pharmacotherapy in Type 2 Diabetes (NICE NG28)
Contemporary NICE guidelines prioritize organ-specific cardiorenal protection over a purely glucose-centric stepped approach. Metformin remains standard initial monotherapy, but dual therapy with an SGLT2 inhibitor is mandated from the outset for individuals with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or high cardiovascular risk.
Drug Class & Agents Mechanism of Action HbA1c Reduction Weight & Hypoglycaemia Profile Cardiorenal Benefits High-Yield Exam Pearls & Adverse Effects
Biguanide ; • Metformin Activates hepatic AMP-activated protein kinase (AMPK); suppresses hepatic gluconeogenesis; improves peripheral insulin sensitivity 1.0 – 1.5 % 1.0\text{–}1.5\% 1.0 – 1.5% ( 11 – 16 mmol/mol 11\text{–}16\text{ mmol/mol} 11 – 16 mmol/mol ) Weight neutral / mild loss;; Zero intrinsic hypoglycaemia Modest CV protection (UKPDS) • GI intolerance (titrate slowly; use modified-release); • Risk of lactic acidosis: check eGFR annually; • Dose review at eGFR < 45 \text{eGFR} < 45 eGFR < 45 ; stop if eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min ; • Long-term use causes vitamin B12 deficiency (malabsorption)
SGLT2 Inhibitors ; • Dapagliflozin; • Empagliflozin; • Canagliflozin Reversibly inhibits sodium-glucose co-transporter 2 in renal proximal convoluted tubule; promotes glycosuria and natriuresis 0.6 – 0.9 % 0.6\text{–}0.9\% 0.6 – 0.9% ( 7 – 10 mmol/mol 7\text{–}10\text{ mmol/mol} 7 – 10 mmol/mol ) Significant weight loss ( 2 – 4 kg 2\text{–}4\text{ kg} 2 – 4 kg );; Negligible hypoglycaemia Profound benefits: ; • Reduces HF hospitalization; • Retards CKD progression; • Lowers MACE in ASCVD • Euglycaemic DKA (stop during acute illness / surgery: "sick day rules"); • Mycotic genital candidiasis & UTIs; • Fournier's gangrene (necrotising fasciitis of perineum); • Volume depletion / orthostatic hypotension
GLP-1 Receptor Agonists ; • Semaglutide; • Dulaglutide; • Liraglutide Incretin mimetic: stimulates GLP-1 receptors; glucose-dependent insulin secretion, glucagon suppression, slows gastric emptying 1.2 – 1.8 % 1.2\text{–}1.8\% 1.2 – 1.8% ( 13 – 20 mmol/mol 13\text{–}20\text{ mmol/mol} 13 – 20 mmol/mol ) Substantial weight loss ( 4 – 8 kg 4\text{–}8\text{ kg} 4 – 8 kg );; Zero intrinsic hypoglycaemia Reduces 3-point MACE in established ASCVD (stroke, MI, CV death) • Nausea, vomiting, diarrhoea (slow titration); • Risk of acute pancreatitis ; • Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2; • NICE criteria: add if BMI ≥ 35 kg/m 2 \text{BMI} \ge 35\text{ kg/m}^2 BMI ≥ 35 kg/m 2 or insulin has occupational hazards
DPP-4 Inhibitors (Gliptins) ; • Sitagliptin; • Linagliptin; • Saxagliptin; • Alogliptin Inhibits dipeptidyl peptidase-4 enzyme, preventing degradation of endogenous incretins (GLP-1 and GIP) 0.5 – 0.8 % 0.5\text{–}0.8\% 0.5 – 0.8% ( 5 – 9 mmol/mol 5\text{–}9\text{ mmol/mol} 5 – 9 mmol/mol ) Weight neutral;; Zero intrinsic hypoglycaemia Cardiovascular neutral (no proven mortality reduction) • Well tolerated; low risk of acute pancreatitis; • Linagliptin: Only gliptin with pure biliary/faecal excretion ( no renal dose adjustment down to dialysis); • Saxagliptin associated with increased risk of heart failure hospitalisation (SAVOR-TIMI)
Sulfonylureas ; • Gliclazide; • Glimepiride Binds SUR1 subunit of ATP-sensitive K + \text{K}^+ K + channels on β \beta β -cells, inducing depolarization, calcium influx, and insulin exocytosis 1.0 – 1.5 % 1.0\text{–}1.5\% 1.0 – 1.5% ( 11 – 16 mmol/mol 11\text{–}16\text{ mmol/mol} 11 – 16 mmol/mol ) Weight gain ( 2 – 4 kg 2\text{–}4\text{ kg} 2 – 4 kg );; High hypoglycaemia risk Neutral (no MACE benefit) • Secondary β \beta β -cell exhaustion over time; • Gliclazide preferred (shorter half-life, inactive liver metabolites); • Glibenclamide contraindicated in renal impairment (accumulates, prolonged fatal hypoglycaemia)
Thiazolidinediones ; • Pioglitazone Agonist of nuclear receptor PPAR- γ \gamma γ ; alters transcription of genes regulating lipid and glucose metabolism; insulin sensitizer 0.8 – 1.2 % 0.8\text{–}1.2\% 0.8 – 1.2% ( 9 – 13 mmol/mol 9\text{–}13\text{ mmol/mol} 9 – 13 mmol/mol ) Weight gain (fluid + adipogenesis);; Zero intrinsic hypoglycaemia Reduces secondary stroke / MI (IRIS trial) • Fluid retention and peripheral oedema: strictly contraindicated in heart failure (NYHA I–IV) ; • Increased risk of fractures (postmenopausal women); • Associated with bladder cancer (avoid in active/uninvestigated macroscopic haematuria)
Insulin Regimens & Initiation Rules
Basal-Bolus (Multiple Daily Injections - MDI): Standard of care for Type 1 DM and advanced Type 2 DM. Consists of once- or twice-daily long-acting basal analogue (insulin glargine U100/U300, insulin degludec, or insulin detemir) plus rapid-acting prandial analogue (insulin aspart, lispro, or glulisine) administered immediately before meals.
Biphasic Premixed Regimens: Fixed ratios of rapid/short-acting insulin with protaminated intermediate insulin (e.g., Novomix 30: 30% soluble aspart, 70% protaminated aspart). Administered twice daily before breakfast and evening meal. Best suited for patients with regular meal patterns requiring simpler injection schedules.
Lipohypertrophy: Proliferation of subcutaneous adipocytes and fibrous tissue triggered by the lipogenic actions of insulin at repeated injection sites. Leads to delayed, erratic insulin absorption and unexplained glycaemic volatility. Prevented by systematic injection site rotation.
- 4. Chronic Microvascular Complications & Surveillance Targets
- Glycaemic Control Targets (NICE NG28)
Lifestyle or Single Agent (not associated with hypoglycaemia, e.g. Metformin): Target HbA1c 48 mmol/mol 48\text{ mmol/mol} 48 mmol/mol ( 6.5 % 6.5\% 6.5% ) .
On Drug Associated with Hypoglycaemia (SU, Insulin) or Dual/Triple Therapy: Target HbA1c 53 mmol/mol 53\text{ mmol/mol} 53 mmol/mol ( 7.0 % 7.0\% 7.0% ) .
Relaxed Individualized Targets ( 58 – 64 mmol/mol 58\text{–}64\text{ mmol/mol} 58 – 64 mmol/mol ): Recommended for frail elderly patients, individuals with severe comorbidities, or those with impaired hypoglycaemia awareness.
Diabetic Retinopathy (DR)
Annual digital retinal screening with mydriatic photography evaluates fundal changes: English National Screening Programme (ENSPDR) Grading:
- R0: No retinopathy
- R1 (Background): Microaneurysms, dot and blot haemorrhages, hard exudates → Routine 12-month recall
- R2 (Pre-proliferative): Venous beading, venous loops, intraretinal microvascular abnormalities (IRMA), multiple blot haemorrhages in all 4 quadrants, cotton wool spots (nerve fibre layer infarcts) → Urgent ophthalmology referral
- R3 (Proliferative): Neovascularisation of disc (NVD) or elsewhere (NVE), pre-retinal/vitreous haemorrhage, tractional retinal detachment → Immediate pan-retinal photocoagulation (PRP) ± anti-VEGF therapy
- Maculopathy (M0 = absent; M1 = present): Exudates or haemorrhages within 1 disc diameter of fovea, or unexplained reduction in visual acuity → Ophthalmology referral; focal laser / intravitreal anti-VEGF (aflibercept, ranibizumab)
Diabetic Nephropathy
Screening: Annual measurement of urinary albumin-to-creatinine ratio (ACR) on early morning spot urine, combined with serum creatinine / eGFR.
Diagnostic Thresholds:
Normal: ACR < 3.0 mg/mmol \text{ACR} < 3.0\text{ mg/mmol} ACR < 3.0 mg/mmol ( < 30 mg/g < 30\text{ mg/g} < 30 mg/g ).
Microalbuminuria (Moderately Increased): ACR 3.0 – 30.0 mg/mmol \text{ACR } 3.0\text{–}30.0\text{ mg/mmol} ACR 3.0 – 30.0 mg/mmol . Requires confirmation on 2 out of 3 morning samples over 3–6 months to exclude transient causes (UTI, strenuous exercise, fever).
Macroalbuminuria (Severely Increased): ACR > 30.0 mg/mmol \text{ACR} > 30.0\text{ mg/mmol} ACR > 30.0 mg/mmol .
Renoprotective Pharmacotherapy:
Type 1 DM: Initiate an ACE inhibitor (or ARB) if confirmed persistent ACR ≥ 3.0 mg/mmol \text{ACR} \ge 3.0\text{ mg/mmol} ACR ≥ 3.0 mg/mmol , irrespective of baseline blood pressure .
Type 2 DM: Initiate an ACE inhibitor (or ARB) if confirmed ACR ≥ 30.0 mg/mmol \text{ACR} \ge 30.0\text{ mg/mmol} ACR ≥ 30.0 mg/mmol , or if ACR 3.0 – 30.0 mg/mmol \text{ACR } 3.0\text{–}30.0\text{ mg/mmol} ACR 3.0 – 30.0 mg/mmol in the presence of hypertension.
SGLT2 Inhibitors: Indicated to retard CKD progression in patients with eGFR 20 – 60 mL/min \text{eGFR } 20\text{–}60\text{ mL/min} eGFR 20 – 60 mL/min or ACR > 22.6 mg/mmol \text{ACR} > 22.6\text{ mg/mmol} ACR > 22.6 mg/mmol (DAPA-CKD, EMPA-KIDNEY trials).
Finerenone: Non-steroidal mineralocorticoid receptor antagonist shown in FIDELIO-DKD to reduce renal and cardiovascular outcomes in CKD associated with T2DM.
Blood Pressure Targets: < 140 / 90 mmHg < 140/90\text{ mmHg} < 140/90 mmHg if ACR < 3.0 mg/mmol \text{ACR} < 3.0\text{ mg/mmol} ACR < 3.0 mg/mmol ; tighter control to < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg if ACR ≥ 3.0 mg/mmol \text{ACR} \ge 3.0\text{ mg/mmol} ACR ≥ 3.0 mg/mmol .
Diabetic Neuropathy & The Diabetic Foot
Distal Symmetric Sensorimotor Polyneuropathy: Chronic "glove and stocking" sensory loss. Earliest signs: loss of vibration perception (128 Hz tuning fork) and loss of protective sensation with 10g Semmes-Weinstein monofilament. Small-fibre neuropathy presents with burning night pain, allodynia, and dysaesthesias. Pharmacotherapy for painful neuropathy: first-line monotherapy with duloxetine, amitriptyline, gabapentin, or pregabalin .
Autonomic Neuropathy:
Cardiovascular: Resting sinus tachycardia, fixed pulse rate, severe orthostatic postural hypotension (fall in systolic BP ≥ 20 mmHg \ge 20\text{ mmHg} ≥ 20 mmHg without compensatory tachycardia; treated with midodrine, fludrocortisone).
Gastrointestinal: Gastroparesis diabeticorum (delayed gastric emptying causing early satiety, nausea, recurrent vomiting, and unpredictable erratic postprandial hypoglycaemia; treated with prokinetics like metoclopramide, erythromycin); diabetic diarrhoea (bacterial overgrowth or nocturnal autonomic hypermotility).
Genitourinary: Atonic neurogenic bladder (urinary retention, overflow incontinence); erectile dysfunction (first-line PDE5 inhibitors).
Sudomotor: Gustatory sweating (facial diaphoresis triggered by food ingestion) and foot anhidrosis.
Diabetic Amyotrophy (Diabetic Lumbosacral Radiculoplexus Neuropathy): Acute, severe asymmetric proximal thigh pain followed by quadriceps muscle wasting and absent knee jerk reflex. Driven by immune-mediated microvasculitis.
Cranial Mononeuropathy: Pupil-sparing diabetic third nerve palsy (ischaemia of the internal motor fibres sparing outer parasympathetic pupillomotor fibres; pupillary light reflex remains completely intact).
Charcot Neuroarthropathy: Acute neuropathic osteoarthropathy triggered by autonomic hyperaemia and minor repetitive trauma. Presents as an acutely swollen, erythematous, warm foot (temperature difference > 2 ∘ C > 2^\circ\text{C} > 2 ∘ C compared to contralateral foot) in a neuropathic limb, often mistaken for cellulitis or gout. Urgent management: non-weight-bearing immobilization in a total contact cast to prevent progressive articular collapse and irreversible "rocker-bottom" foot deformity.